These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Tenascin-C levels in the vitreous of patients with proliferative vitreoretinopathy. Mitamura Y; Takeuchi S; Ohtsuka K; Matsuda A; Yamamoto T; Yamamoto S; Hiraiwa N; Kusakabe M Ophthalmologica; 2003; 217(6):422-5. PubMed ID: 14573976 [TBL] [Abstract][Full Text] [Related]
9. Immunoreactive ET-1 in the vitreous humor and epiretinal membranes of patients with proliferative vitreoretinopathy. Roldán-Pallarés M; Rollín R; Mediero A; Martínez-Montero JC; Fernández-Cruz A; Bravo-Llata C; Fernández-Durango R Mol Vis; 2005 Jul; 11():461-71. PubMed ID: 16030497 [TBL] [Abstract][Full Text] [Related]
10. Vitreous inflammatory and angiogenic factors on patients with proliferative diabetic retinopathy or diabetic macular edema: the role of Lipocalin2. Batsos G; Christodoulou E; Christou EE; Galanis P; Katsanos A; Limberis L; Stefaniotou M BMC Ophthalmol; 2022 Dec; 22(1):496. PubMed ID: 36536319 [TBL] [Abstract][Full Text] [Related]
11. Intercellular adhesion molecule-1 in proliferative vitreoretinopathy. Limb GA; Chignell AH; Cole CJ; Green WT; Webster L; Hollifield RD; Dumonde DC Invest Ophthalmol Vis Sci; 1997 Apr; 38(5):1043-8. PubMed ID: 9113001 [TBL] [Abstract][Full Text] [Related]
12. CONCENTRATIONS OF VITREAL CYTOKINES IN RHEGMATOGENOUS RETINAL DETACHMENT. Danielescu C; Zugun-Eloae F; Zlei M Rev Med Chir Soc Med Nat Iasi; 2016; 120(1):124-9. PubMed ID: 27125084 [TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor levels in the vitreous of patients with proliferative vitreoretinopathy. Mitamura Y; Takeuchi S; Matsuda A; Tagawa Y; Mizue Y; Nishihira J Am J Ophthalmol; 2000 May; 129(5):678-80. PubMed ID: 10844070 [TBL] [Abstract][Full Text] [Related]
14. Position of macula lutea and presence of proliferative vitreoretinopathy affect vitreous cytokine expression in rhegmatogenous retinal detachment. Balogh A; Milibák T; Szabó V; Nagy ZZ; Resch MD PLoS One; 2020; 15(6):e0234525. PubMed ID: 32542038 [TBL] [Abstract][Full Text] [Related]
15. The role of thrombin in proliferative vitreoretinopathy. Bastiaans J; van Meurs JC; Mulder VC; Nagtzaam NM; Smits-te Nijenhuis M; Dufour-van den Goorbergh DC; van Hagen PM; Hooijkaas H; Dik WA Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4659-66. PubMed ID: 25015355 [TBL] [Abstract][Full Text] [Related]
17. Vitreous M2 Macrophage-Derived Microparticles Promote RPE Cell Proliferation and Migration in Traumatic Proliferative Vitreoretinopathy. Song Y; Liao M; Zhao X; Han H; Dong X; Wang X; Du M; Yan H Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):26. PubMed ID: 34554178 [TBL] [Abstract][Full Text] [Related]
18. Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative vitreoretinopathy. Mitamura Y; Takeuchi S; Matsuda A; Tagawa Y; Mizue Y; Nishihira J Am J Ophthalmol; 1999 Dec; 128(6):763-5. PubMed ID: 10612518 [TBL] [Abstract][Full Text] [Related]
19. Upregulation of RAGE and its ligands in proliferative retinal disease. Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297 [TBL] [Abstract][Full Text] [Related]
20. Cell proliferation in human epiretinal membranes: characterization of cell types and correlation with disease condition and duration. Oberstein SY; Byun J; Herrera D; Chapin EA; Fisher SK; Lewis GP Mol Vis; 2011; 17():1794-805. PubMed ID: 21750605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]